BBBrunella Barbaro

Brunella Barbaro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brunella Barbaro has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The potential predictive value of MRI and PET-CT in mucinous and nonmucinous rectal cancer to identify patients at high risk of metastatic disease

    by Brunella Barbaro, Lucia Leccisotti, Fabio M Vecchio, Marialuisa Di Matteo, Teresa Serra, Marco Salsano, Andrea Poscia, Claudio Coco, Roberto Persiani, Sergio Alfieri, et al.

    Objective:To correlate imaging parameters from baseline MRI diffusion-weighted imaging (DWI) and fludeoxyglucose (FDG) positron emission tomography (PET)-CT with synchronous and metachronous metastases in mucinous carcinoma (MC) and non-mucinous carcinoma (NMC) rectal cancer.Methods:111 patients with extraperitoneal locally advanced rectal cancer, who underwent pelvic MRI, DWI and FDG PET-CT, were stratified into MC (n = 23) and NMC (n = 88). We correlated adverse morphologic features on MRI [mT4, mesorectal fascia involvement, extramural venous invasion (mEMVI), mN2] and quantitative imaging parameters [minimum apparent diffusion coefficient (ADCmin), maximum standardized uptake value, total lesion glycolysis, metabolic tumour volume, T2 weighted and DWI tumour volumes] with the presence of metastatic disease. All patients underwent pre-operative chemoradiation therapy (CRT); 100/111 patients underwent surgery after CRT and were classified as pathological complete response (PCR) and no PCR [tumour regres...


  • International consensus guidelines on Clinical Target Volume delineation in rectal cancer

    by Vincenzo Valentini, Maria Antonietta Gambacorta, Brunella Barbaro, Giuditta Chiloiro, Claudio Coco, Prajnan Das, Francesco Fanfani, Ines Joye, Lisa Kachnic, Philippe Maingon, et al.


  • 703 Prospective Trial of PillCam Colon Capsule (CCE) vs CT-Colonography (CTC) in the Evaluation of Patients With Incomplete Conventional Colonoscopy (CC): an Interim Analysis

    by Cristiano Spada, Cesare Hassan, Paola Cesaro, Brunella Barbaro, Franco Iafrate, Lucio Petruzziello, Leonardo Minelli, Marcella Iannitti, Marco Salsano, Giuseppe Alvaro, et al.


  • Is two-dimensional field definition sufficient for pelvic node coverage in rectal cancer compared to technical three-dimensional definition?

    by Maria Antonietta Gambacorta, Danilo Pasini, Bd Minsky, Stefano Arcangeli, Alice Mannocci, Maria Cristina Barba, Brunella Barbaro, Stefania Manfrida, Mario Balducci, Vincenzo Valentini

    To assess the effectiveness of the potential advantages with 3-dimensional-based treatment planning versus 2-dimensional pelvic bone-based treatment planning in patients with rectal cancer, controlled for clinical stage


  • Diffusion-Weighted Magnetic Resonance Imaging in Monitoring Rectal Cancer Response to Neoadjuvant Chemoradiotherapy

    by Brunella Barbaro, Renata Vitale, Vincenzo Valentini, Sonia Illuminati, Fabio M. Vecchio, Gianluca Rizzo, Maria Antonietta Gambacorta, Claudio Coco, Antonio Crucitti, Roberto Persiani, et al.


  • Hepatic veins in presurgical planning of hepatic resection: what a radiologist should know

    by Brunella Barbaro, Giovanna Soglia, Giuseppe Alvaro, Maria Vellone, Felice Giuliante, Gennaro Nuzzo, Lorenzo Bonomo

    Hepatic resection is considered to be feasible when all malignant nodules can be technically excised. The goal of the surgical approach is to optimize the oncologic resection (negative margins), sparing the non-cancerous hepatic parenchyma. The outflowing hepatic vein (HV) of that particular liver remnant must be intact in order to preserve its function. The purpose of this article is to familiarize radiologists with anatomy and anatomical variants of HVs, with special emphasis on segmental venous drainage for presurgical planning of hepatic resections. We focus on information which radiologist should give to hepatic surgeon to choose proper surgical approach. Radiologist’s familiarity with the anatomy and anatomical variants of HVs is essential for accurate surgical planning to avoid venous congestion as postoperative complication. Any clinically important hepatic vein variation detected on presurgical imaging should be carefully recorded in the radiology report.


  • Restaging Locally Advanced Rectal Cancer with MR Imaging after Chemoradiation Therapy

    by Brunella Barbaro, Renata Vitale, Lucia Leccisotti, Fabio M. Vecchio, Luisa Santoro, Vincenzo Valentini, Claudio Coco, Fabio Pacelli, Antonio Crucitti, Roberto Persiani, et al.

    In recent years, preoperative therapy has become standard procedure for locally advanced rectal cancer. Tumor shrinkage due to preoperative chemotherapy-radiation therapy (CRT) is now a reality, and pathologically complete responses are not uncommon. Some researchers are now addressing organ preservation, thus increasing the demand for both functional and morphologic radiologic evaluation of response to CRT to distinguish responding from nonresponding tumors. On magnetic resonance (MR) images, post-CRT tumor morphologic features and volume changes have a high positive predictive value but a low negative predictive value for assessing response. Preliminary results indicate that diffusion-weighted MR imaging, especially at high b values, would be effective for prediction of treatment outcome and for early detection of tumor response. Some authors have reported that the use of apparent diffusion coefficient values in combination with other MR imaging criteria significantly improves discrimination between malignant and benign lymph nodes. Sequential determination of fluorodeoxyglucose uptake at positron emission tomography/computed tomography has proved useful in differentiating responding from nonresponding tumors during and at the end of CRT. However, radionuclide techniques have limitations, such as low spatial resolution and high cost. Large studies will be needed to verify the most effective morphologic and functional imaging modalities for post-CRT restaging of rectal cancer. Supplemental material available at http://radiographics.rsna.org/lookup/suppl/doi:10.1148/rg.303095085/-/DC1.


  • Authors’ Response

    by Brunella Barbaro, Renata Vitale, Lucia Leccisotti, Fabio M. Vecchio, Luisa Santoro, Vincenzo Valentini, Claudio Coco, Fabio Pacelli, Antonio Crucitti, Roberto Persiani, et al.

  • Preoperative right portal vein embolisation: indications and results

    by B. Barbaro, F. Caputo, C. Tebala, C. Di Stasi, M. Vellone, F. Giuliante, G. Nuzzo, L. Bonomo

    The purpose of this retrospective study was to evaluate the efficacy of right portal vein embolisation (PVE) in inducing contralateral liver hypertrophy before extended hepatectomy. Twenty-six consecutive patients, 14 with liver metastases (ten from colorectal cancer; four from carcinoid tumours) and 12 with biliary cancers (ten Klatskin tumours; one gallbladder tumour; one intrahepatic cholangiocarcinoma) with insufficient predicted future remnant liver (FRL) underwent right PVE to induce hypertrophy of the contralateral hemiliver prior to surgical resection. Total liver volume, tumour volume and FRL volume were calculated on a 3D workstation. The ratio of the FRL to the total functional liver volume was <30% in all patients. The FRL volume increased by 5%–25% (15% on average) after right PVE in patients with liver metastases and by 9%–19% (14% on average) in patients with biliary cancers. In all patients, the ratio of FRL to functional liver volume was ≥30% after right PVE. No postoperative deaths due to severe liver failure occurred in the 20 patients who underwent extended hepatectomy. Right PVE extends the indications for hepatectomy in patients with liver metastases and those with biliary cancers who have an insufficient potential hepatic functional reserve. Lo scopo del nostro studio retrospettivo è stato di valutare l’efficacia dell’embolizzazione del ramo portale destro (RPVE) come trattamento pre-chirurgico per indurre l’ipertrofia del fegato sinistro in pazienti candidati a resezione epatica. Ventisei pazienti consecutivi, 14 portatori di metastasi epatiche (colon-retto, 10 pazienti; carcinoide, 4 pazienti) e 12 portatori di neoplasia delle vie biliari (neoplasia di Klatskin, 10 pazienti; neoplasia della colecisti, 1 paziente; colangiocarcinoma intraepatico, 1 paziente) con potenziale riserva funzionale epatica (FRL) insufficiente sotto stati sottoposti a RPVE come trattamento pre-chirurgico. Mediante una workstation 3D è stato calcolato il volume epatico totale, il volume del tumore ed il volume del FRL. In tutti i pazienti il rapporto FRL/ volume epatico totale funzionante era <30%. Il volume del FRL ha dimostrato un incremento volumetrico compreso tra il 5%–25% (15% in media) dopo RPVE nei pazienti con metastasi epatiche e tra il 9%–19% (14% in media) in pazienti con neoplasie biliari. In tutti i pazienti il rapporto FRL/volume epatico funzionante dopo RPVE era <30%. Venti pazienti sono stati sottoposti a chirurgia resettiva epatica e nessun paziente è deceduto per insufficienza epatica grave. L’embolizzazione portale allarga le indicazioni alla chirurgia resettiva epatica in pazienti con metastasi epatiche e neoplasie delle vie biliari con potenziale riserva funzionale insufficiente.